What is your approach to a patient with an EGFR exon 19 mutated NSCLC who develops progression on osimertinib and repeat biopsy demonstrates the EGFR exon 19 mutation and a new BRAF V600E mutation?
Community PollStarted
What is your approach to a patient with an EGFR exon 19 mutation who develops progression on osimertinib and repeat biopsy demonstrates the EGFR exon 19 mutation and a new BRAF V600E mutation?
171 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Answered on
I have a couple of these patients - and the triplet combo seems to be helping them. There is really no good data to support this combination. However, the AE profile of these agents are different and combination should not increase toxicity theoretically. BRAF, MET, and EGFR are all on chromosome 7 ...
Join for free or sign in to see the full answer